Committees

Drugs policy: medicinal cannabis inquiry

Inquiry

As the first part of a wider inquiry into the impact of drugs policy on public health, the Committee sought evidence on the usage of medicinal cannabis products. The Committee invited written submissions answering the following:

  • What does the current evidence base tell us about the efficacy of medicinal cannabis?
  • What plans are there for research into the medicinal use of cannabis, and what challenges are faced by that research?
  • How suitable are the current procedures for enabling the use of medicinal cannabis in appropriate cases?
  • Do practitioners have the knowledge and products available to them to confidently prescribe medicinal cannabis?
  • Is the current guidance around prescribing CDMPs fit for purpose? 
  • What can we learn from the legalisation of medicinal cannabis and its practical implementation in other countries?
  • Have recent changes in the scheduling and availability of CDMP, and media attention around this, affected public opinion and behaviours in the UK?

Reports, special reports and government responses

View all reports and responses
16th Report - Drugs policy: medicinal cannabis
Inquiry Drugs policy: medicinal cannabis inquiry
Open PDF
Opens in new window
Open HTML
Opens in new window
HC 1821
Report
Response to this report
Drugs policy: medicinal cannabis: Government Response to the Committee's Sixteenth Report
Open PDF
Opens in new window
CP 171
Government Response

Oral evidence transcripts

View all oral evidence transcripts
26 March 2019
Inquiry Drugs policy: medicinal cannabis inquiry
Witnesses Professor Andrew Goddard, President, Royal College of Physicians, Professor Finbar O'Callaghan, President, British Paediatric Neurology AssociationBaroness Blackwood, Parliamentary Under Secretary of State, Professor Chris Whitty, Chief Scientific Advisor, Department of Health and Social Care, Nick Hurd MP, Minister of State for Policing and the Fire Service, Home Office, Dr Keith Ridge, Chief Pharmaceutical Officer, NHS England
Open PDF
300KB
Open HTML
344KB
Oral Evidence
19 March 2019
Inquiry Drugs policy: medicinal cannabis inquiry
Witnesses Professor Dame Sally Davies, Chief Medical Officer for England, Alette Addison, Head of Pharmacy Development and Regulation, Department of Health and Social CareGenevieve Edwards, Director of External Affairs, MS Society, Professor Mike Barnes, Interim Chair, Medical Cannabis Clinicians' Society, Peter Carroll, Campaign Director, End Our PainProfessor Helen Cross, Head of Developmental Neurosciences, UCL GOS Institute of Child Health, Dr Imran Malik, Committee member, Royal College of Psychiatrists, Professor Sanjay Sisodiya, Chair of the ABN Epilepsy Advisory Group, Association of British Neurologists
Open PDF
373KB
Open HTML
458KB
Oral Evidence

Written evidence

View all written evidence
GW Pharmaceuticals (DMC0102)
Open PDF
67KB
Open HTML
18KB
Department of Health and Social Care (DMC0101)
Open PDF
108KB
Open HTML
26KB
Suprex (DMC0100)
Open PDF
47KB
Open HTML
15KB

Other publications

Government Responses
The Government has undertaken to respond to most committee reports within two months, although there are exceptions to this rule.
1 published

Contact us

We can't usually help you with an individual problem or a specific complaint.

  • Email: hsccom@parliament.uk
  • Phone: (general enquiries) 020 7219 6182 | 020 7219 6832 (media enquiries)
  • Address: Health and Social Care Committee, House of Commons, London, SW1A 0AA